Supernus Pharmaceuticals (NASDAQ:SUPN) Posts Quarterly Earnings Results, Beats Estimates By $0.25 EPS

Supernus Pharmaceuticals (NASDAQ:SUPN) posted its quarterly earnings results on Monday. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.44 by $0.25, Briefing.com reports. Supernus Pharmaceuticals had a net margin of 0.83% and a return on equity of 0.56%. The business had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. During the same quarter in the previous year, the firm posted ($0.29) earnings per share. The company’s quarterly revenue was up 14.2% compared to the same quarter last year. Supernus Pharmaceuticals updated its FY 2024 guidance to EPS.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $34.70 on Tuesday. Supernus Pharmaceuticals has a one year low of $23.05 and a one year high of $35.56. The firm has a market cap of $1.91 billion, a PE ratio of 385.56 and a beta of 0.86. The firm’s fifty day moving average is $33.02 and its two-hundred day moving average is $30.46.

Analysts Set New Price Targets

A number of brokerages have issued reports on SUPN. Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.